Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?

Detalles Bibliográficos
Autores principales: Evans, Marc, Dejager, Sylvie, Schweizer, Anja, Foley, James E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374076/
https://www.ncbi.nlm.nih.gov/pubmed/25783754
http://dx.doi.org/10.1007/s13300-015-0104-4
_version_ 1782363426491727872
author Evans, Marc
Dejager, Sylvie
Schweizer, Anja
Foley, James E.
author_facet Evans, Marc
Dejager, Sylvie
Schweizer, Anja
Foley, James E.
author_sort Evans, Marc
collection PubMed
description
format Online
Article
Text
id pubmed-4374076
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-43740762015-03-30 Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease? Evans, Marc Dejager, Sylvie Schweizer, Anja Foley, James E. Diabetes Ther Commentary Springer Healthcare 2015-03-18 2015-03 /pmc/articles/PMC4374076/ /pubmed/25783754 http://dx.doi.org/10.1007/s13300-015-0104-4 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Commentary
Evans, Marc
Dejager, Sylvie
Schweizer, Anja
Foley, James E.
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
title Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
title_full Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
title_fullStr Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
title_full_unstemmed Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
title_short Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?
title_sort is there evidence of any safety differences among dpp-4 inhibitors in the treatment of people with type 2 diabetes mellitus and reduced gfr due to chronic kidney disease?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374076/
https://www.ncbi.nlm.nih.gov/pubmed/25783754
http://dx.doi.org/10.1007/s13300-015-0104-4
work_keys_str_mv AT evansmarc isthereevidenceofanysafetydifferencesamongdpp4inhibitorsinthetreatmentofpeoplewithtype2diabetesmellitusandreducedgfrduetochronickidneydisease
AT dejagersylvie isthereevidenceofanysafetydifferencesamongdpp4inhibitorsinthetreatmentofpeoplewithtype2diabetesmellitusandreducedgfrduetochronickidneydisease
AT schweizeranja isthereevidenceofanysafetydifferencesamongdpp4inhibitorsinthetreatmentofpeoplewithtype2diabetesmellitusandreducedgfrduetochronickidneydisease
AT foleyjamese isthereevidenceofanysafetydifferencesamongdpp4inhibitorsinthetreatmentofpeoplewithtype2diabetesmellitusandreducedgfrduetochronickidneydisease

Ejemplares similares